A future where the body can truly heal itself is within reach. MicroCures is pioneering pro-regenerative siRNA therapies that activate the body’s intrinsic repair machinery—helping tissues rebuild, nerves regrow, and function return.
At the center of this platform is an siRNA that temporarily silences FL2. FL2 is an intracellular enzyme that normally regulates cell growth and movement — but becomes overexpressed during injury, excessively restricting the cells needed for repair. By working inside cells, our therapies unlock natural repair processes in ways surface-level treatments cannot.
We are on a mission is to bring biologically intelligent, clinically practical regenerative medicine to patients who currently lack effective options.
Regenerative medicine is shifting from passive protection to active restoration. Traditional treatments often manage symptoms or provide temporary support—but rarely address the biological barriers that keep tissues from healing.
Pro-regenerative therapies introduce a new model: one that activates the body’s own repair programs to rebuild structure, restore function, and reduce reliance on repeat interventions.
Gages natural repair pathways rather than adding external growth factors
Supports tissue recovery and nerve regeneration
Acts directly at the site of injury
Designed for real-world use and patient-friendly workflows
Our technology lifts the internal barriers that keep damaged tissue from healing. Using a targeted siRNA sequence, we temporarily reduce FL2—an intracellular enzyme that slows cell and nerve movement after injury.
With this barrier removed, cells regain their ability to migrate, tissues close more quickly, and nerves can regrow along natural pathways. The treatment stays where it’s placed, works only for a short time, and supports the body’s own repair programs.
We’re applying this approach first in neurotrophic keratitis, where restoring natural corneal healing can significantly change outcomes.
Affecting an estimated 150,000 people in the U.S., neurotrophic keratitis (NK) is a rare, degenerative ocular surface disease in which loss of corneal sensation prevents the eye from recognizing damage and initiating repair.¹ Small injuries can progress into chronic wounds, scarring, and vision loss. Current treatments rely on frequent dosing or external growth factors, leaving significant unmet need.
MCR-231 is the first siRNA-based, intracellular pro-regenerative therapy designed to activate intrinsic corneal healing through temporary FL2 silencing. It delivers our proprietary FL2-silencing siRNA (siFi2) in a topical lipid nanoparticle formulation, enabling precise, localized delivery directly to the cornea.
Peripheral nerve repair – enhancing axonal extension and functional recovery
Dermal wound healing – supporting closure of chronic or complex wounds
CNS injury – early research examining support for axonal growth
Explore the latest research, publications, and company milestones shaping the future of pro-regenerative medicine. From peer-reviewed studies to development updates, this is where our scientific and clinical progress comes to life.
